Fox Corp. (Class B) shares are trading steadily on Nasdaq following their early May quarterly results, with investors continuing to assess the earnings metrics and valuation multiples. The market has absorbed the latest data without significant repricing, balancing advertising and sports-rights challenges against the strength of Fox's news and live sports franchises. The stock's valuation places it in the mid-range of its peer group, supported by its cash-generative profile and capital return programs.

Jyong Biotech is advancing Botreso, a plant-based drug targeting benign prostatic hyperplasia (BPH) with 12.2 million US patients, and a prostate cancer prevention asset, PCP. The company highlighted its FDA pathway, which includes additional US studies, aiming for a combined NDA submission for Botreso by 2029-2030. CEO Fu-Feng Kuo emphasized the need for efficacious treatments with low side-effect profiles, prioritizing US FDA approval for premium pricing and accelerated global market access.

Kohl's (KSS) stock has been upgraded to a buy rating following better-than-expected Q1 results and a 20% post-earnings rally, despite a 20% year-to-date decline. The company is seeing positive comparable sales in key categories like women’s, kids, and home decor, indicating a potential fundamental rebound. Its focus on value, proprietary brands, and extensive national presence, combined with a compelling low-teens P/E multiple compared to peers, positions KSS for upside in a challenging macroeconomic environment.

Jack Henry & Associates Inc. (Nasdaq: JKHY) announced that its President & CEO, Greg Adelson, and CFO & Treasurer, Mimi Carsley, will present at several upcoming investor conferences in June 2026. Greg Adelson will speak at the RBC Capital Markets Financial Technology Conference and the Morgan Stanley US Financials Conference, while Mimi Carsley will present at the William Blair 46th Annual Growth Stock Conference and the Baird 2026 Global Consumer, Technology & Services Conference. Live webcasts and replays of these presentations will be available.

Best Buy Co., Inc. (NYSE:BBY) announced that its Board of Directors has authorized a regular quarterly cash dividend of $0.96 per common share. This dividend is payable on July 9, 2026, to shareholders recorded as of June 18, 2026. The company had over 210 million shares of common stock outstanding as of early May 2026.

LGI Homes announced the grand opening of Trails West, a new 529-lot master-planned community in west Jacksonville, offering homes from the $240s across nine floor plans. The community, located approximately 30 minutes southwest of downtown, will feature an amenity package including walking paths, a soccer field, dog parks, and a tot lot, slated for completion in late 2026. This development expands LGI Homes' presence in the Jacksonville area, aiming to provide affordable, high-quality homes with strong long-term investment potential.

CVS Health received the 2026 Newsweek AI Impact Award in the AI Health Care category for Best Outcomes – Patient Care. The award recognizes CVS Health's AI-Driven Prescription Interpretation and Instruction Standardization technology, which uses large language models to interpret complex prescription directions and calculate precise dosage, reducing manual transcription and speeding up prescription fulfillment. This AI implementation allows pharmacists more time for direct patient support while maintaining their final clinical authority through "human-in-the-loop" safeguards.

Jyong Biotech's CEO, Ms. Fu-Feng Kuo, detailed the company's FDA pathway and global strategy in a PharmaBoardroom interview. The company is developing plant-derived therapeutics, notably Botreso® for benign prostatic hyperplasia (BPH), and emphasizes a strong focus on the U.S. market for regulatory approval. Jyong Biotech aims to address chronic disease management with efficacious treatments that have low side-effect profiles.

AbbVie Inc. (NYSE: ABBV) has received European Commission authorization to expand the label for its cancer drug VENCLYXTO. This approval allows for new combination treatments involving VENCLYXTO with acalabrutinib (with or without obinutuzumab) and with ibrutinib for adult patients with previously untreated chronic lymphocytic leukemia (CLL) across the EU, Iceland, Norway, and Liechtenstein. These expanded indications are based on positive data from the Phase 3 AMPLIFY, Phase 3 GLOW, and Phase 2 CAPTIVATE clinical trials, offering fixed-duration, oral treatment options.

Jack Henry & Associates (Nasdaq: JKHY) announced that its President & CEO, Greg Adelson, and CFO & Treasurer, Mimi Carsley, will participate in four investor conferences in June 2026. The executives will present at events hosted by RBC Capital Markets, Morgan Stanley, William Blair, and Baird, with live webcasts and replays available. This provides an opportunity for investors to gain insights into the company's strategies and financial performance.